3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Primary Myelofibrosis
23
Myeloproliferative Disorders
15
Leukemia, Myeloid, Acute
14
Polycythemia Vera
10
Leukemia
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Myelodysplastic Syndromes
9
Graft vs Host Disease
8
Thrombocythemia, Essential
7
Recurrence
6
Neoplasms
6
Lymphoma, T-Cell
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Myelodysplastic-Myeloproliferative Diseases
3
Lymphoma, T-Cell, Cutaneous
3
Leukemia, Prolymphocytic, T-Cell
3
Leukemia, Myelomonocytic, Chronic
3
Hematologic Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Bronchiolitis Obliterans Syndrome
3
Triple Negative Breast Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Interventions
ruxolitinib
1
ceterizine hydrochloride
1
capivasertib
1
Sirolimus
1
Loperamide
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Exanthema
×
ruxolitinib
×
1 year
×
Clear all
NCT06399029
2026-04-30
TRUX-LST
University of Zurich
Phase 2
Active not recruiting
22 enrolled